Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.73 |
| ▸ | CTSL | P07711 | 4/20 | 0.68 |
| ▸ | CTSV | O60911 | 1/20 | 0.68 |
| ▸ | CTSB | P07858 | 1/20 | 0.68 |
| ▸ | CTSS | P25774 | 1/20 | 0.68 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373391 | 0.92 | CTSK (0.85) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL5742250 | 0.89 | CTSK (0.85) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL8296643 | 0.88 | CTSK (0.58) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL2155575 | 0.85 | CTSK (0.75) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL2156371 | 0.85 | CTSK (0.85) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL14337583 | 0.85 | CTSK (0.73) | CTSKCTSLCTSVCTSBCTSS | |
| Bicarbonate SCHEMBL15752120 | 0.84 | CTSK (0.69) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL2156489 | 0.84 | CTSK (0.82) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL2155588 | 0.84 | CTSK (0.82) | CTSKCTSLCTSVCTSBCTSS | |
| SCHEMBL4992553 | 0.84 | CTSK (0.82) | CTSKCTSLCTSVCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673336-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2014-06-04 | — | — | EP | claimed |
| US-7312353-B2 | Cathespin cysteine protease inhibitors | MERCK FROST CANADA & CO. (CA) | 2007-12-25 | — | — | US | claimed |
| US-20060287373-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-12-21 | — | — | US | claimed |
| EP-1673336-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2014-06-04 | — | — | EP | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-7312353-B2 | Cathespin cysteine protease inhibitors | MERCK FROST CANADA & CO. (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312353-B2 | Cathespin cysteine protease inhibitors | MERCK FROST CANADA & CO. (CA) | 2007-12-25 | — | — | US | disclosed |
| US-20060287373-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | CTSK 1815/4885CTSL 1564/4885CTSV 2412/4885 |
| US-20060287373-A1 | Cathepsin cysteine protease inhibitors | CTSE, CTSS, CTSB | CTSK 5/4885CTSL 9/4885CTSV 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.